Business Description
Perseus Proteomics Inc
ISIN : JP3836800007
Description
Perseus Proteomics Inc is engaged in the research and development, manufacture, and sales of pharmaceuticals. It provides antibody based therapeutics and diagnostics drugs to cure against cancer and other diseases.
Financial Strength
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | No Debt | |||||
| Equity-to-Asset | 0.87 | |||||
| Interest Coverage | No Debt | |||||
| Piotroski F-Score | 4/9 | |||||
| Altman Z-Score | 5.83 | |||||
| Beneish M-Score | -0.47 | |||||
| WACC vs ROIC | ||||||
Growth Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -5.2 | |||||
| 3-Year EBITDA Growth Rate | 12.9 | |||||
| 3-Year EPS without NRI Growth Rate | 12.9 | |||||
| 3-Year FCF Growth Rate | 2.3 | |||||
| 3-Year Book Growth Rate | 56.4 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 71.44 | |||||
| 9-Day RSI | 61.9 | |||||
| 14-Day RSI | 52.66 | |||||
| 6-1 Month Momentum % | -24.21 | |||||
| 12-1 Month Momentum % | 16.32 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 17.61 | |||||
| Quick Ratio | 17.58 | |||||
| Cash Ratio | 16.7 | |||||
| Days Inventory | 143.71 | |||||
| Days Sales Outstanding | 39.76 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -8.9 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 89.01 | |||||
| Operating Margin % | -947.33 | |||||
| Net Margin % | -1168.66 | |||||
| FCF Margin % | -763.71 | |||||
| ROE % | -54.42 | |||||
| ROA % | -49.97 | |||||
| ROIC % | -943.1 | |||||
| ROCE % | -42.31 |
GF Value Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 42.09 | |||||
| PB Ratio | 2.62 | |||||
| Price-to-Tangible-Book | 2.62 | |||||
| EV-to-EBIT | -2.64 | |||||
| EV-to-EBITDA | -2.64 | |||||
| EV-to-Revenue | 25.02 | |||||
| EV-to-FCF | -2.57 | |||||
| Price-to-Net-Current-Asset-Value | 2.69 | |||||
| Price-to-Net-Cash | 2.86 | |||||
| Earnings Yield (Greenblatt) % | -37.86 | |||||
| FCF Yield % | -18.06 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Perseus Proteomics Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil 円) | 96.218 | ||
| EPS (TTM) (円) | -95.574 | ||
| Beta | 0 | ||
| Volatility % | 113.06 | ||
| 14-Day RSI | 52.66 | ||
| 14-Day ATR (円) | 19.016224 | ||
| 20-Day SMA (円) | 318.15 | ||
| 12-1 Month Momentum % | 16.32 | ||
| 52-Week Range (円) | 255 - 879 | ||
| Shares Outstanding (Mil) | 11.83 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Perseus Proteomics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Perseus Proteomics Inc Stock Events
| Event | Date | Price(円) | ||
|---|---|---|---|---|
| No Event Data | ||||
Perseus Proteomics Inc Frequently Asked Questions
What is Perseus Proteomics Inc(TSE:4882)'s stock price today?
The current price of TSE:4882 is 円344.00. The 52 week high of TSE:4882 is 円879.00 and 52 week low is 円255.00.
When is next earnings date of Perseus Proteomics Inc(TSE:4882)?
The next earnings date of Perseus Proteomics Inc(TSE:4882) is .
Does Perseus Proteomics Inc(TSE:4882) pay dividends? If so, how much?
Perseus Proteomics Inc(TSE:4882) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers